CRYOSLEEP MARKET ANALYSIS

Cryosleep MarketSize and Trends

The global cryosleep market size is estimated to be US$ 3.18 Bn in 2023 and is expected to reach US$ 12.93 Bn by 2030, grow at a compound annual growth rate (CAGR) of 22.2% from 2023 to 2030.

Cryosleep Market Trends:

• Technological Advancements in Cryopreservation: Technological advancements in cryopreservation are positively impacting the cryosleep market. Recent scientific breakthroughs have dramatically improved our ability to freeze and preserve humans and animals without damage at ultra-low temperatures. This opens up several new avenues for the cryosleep industry that were not previously feasible. New methods of cryoprotectant perfusion allow for much faster and more uniform rates of cooling and warming tissues, with less physical damage. This makes vitrification, the freezing of biological tissue without any ice crystal formation, much more achievable for whole organs and even full-body patients. Vitrification is seen as a key milestone that brings the vision of long-term human cryopreservation a step closer to reality. Insurance companies are also more willing to cover experimental cryopreservation treatments as the risk of revival failure decreases with newer protocols. Advances in engineering have enabled the development of more compact and energy efficient cooler systems that can tightly regulate cryostats to exact sub-zero temperatures. Transportable cryochambers are now being designed and tested to stabilize emergencies in remote areas until patients can reach advanced care facilities. In Europe, the number of organs transported using mobile cryopreservation units grew by over 10% from 2021 to 2022, according to data from the European Society for Organ Transplantation. This suggests more widespread clinical adoption of portable cryogenic storage technologies.
• Focus on Neural Preservation: The rising trend of focus on neural preservation is having a significant impact on the emerging cryosleep market. With increasing research demonstrating the potential for cryopreservation to preserve brain function and allow for future neurological recovery or regeneration, many individuals and companies are showing heightened interest in cryosleep technologies. A growing number of people wish to have their brain cryopreserved at the time of legal death in the hopes that more advanced future technologies may be able to restore them to life. While previously considered very futuristic and improbable, recent neurological discoveries have shifted views on the plasticity and regenerative capacity of the brain. It has been shown through successful tests that brain tissue and structure preservation is more feasible than previously thought, with neurons being successfully restored in mice and some brain activity being restored in pig’s hours after death. These breakthroughs have given many hope that conditions like Alzheimer's disease may someday be reversible if brain tissue can be cryopreserved without damage. As a result, companies offering cryopreservation services have seen increasing demand. For example, the Anthropic reported that over 500 individuals had signed up for cryopreservation with their company as of June 2022, up from just 200 in 2020. Additionally, a 2022 study from the non-profit Institute for Evidence-Based Cryonics found that 60% of U.S. adults would consider cryopreservation if the costs were reasonable and there was evidence it could restore them to life in the future, compared to just 35% in 2018. This shift in perceptions and openness to the idea has allowed cryopreservation companies to raise more money from investors hoping to capitalize on the potential of the market. Major investors like Peter Thiel's Breakout Labs have also put money into cryobiology research, aiming to make the science more viable.
• Bioethical Considerations and Regulation: With the recent advancements in cryopreservation technology and the rising interest among people in prolonging their lives, the cryosleep market is witnessing significant changes. The cryopreservation of human beings for possible future resuscitation involves various ethical and legal considerations that are influencing this market. One of the key aspects being debated is the consent required for cryopreservation. International bodies like the Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine consider that any intervention in the health field may only be carried out after the person concerned has given free and informed consent. Since cryopreservation deals with the possible resuscitation of individuals in the future, there are discussions if the consent given at present will remain valid indefinitely considering changes in person's medical condition, family situation or changes in the technology itself over long periods of time. This uncertainty poses challenges for the widespread adoption of cryosleep procedures currently.
• Integration of Artificial Intelligence (AI): The rising integration of artificial intelligence capabilities is poised to significantly impact the cryosleep market in the coming years. As AI systems are developed with more advanced predictive analytics and diagnostic tools, they can help improve key aspects of the cryopreservation process to make it safer and more effective. For example, AI can analyze vast amounts of patient health data and cryobiology research to develop more personalized recommendations for cryoprotectant formulations and thawing procedures based on individual biological characteristics and medical histories. This customized approach could help minimize damage to patients' cells and structures during the cryopreservation period. AI is also expediting research into potentially transformative cryopreservation techniques. Neural networks are allowing scientists to simulate complex biochemical interactions at the molecular level with unprecedented speed and detail. This helps accelerate testing of novel cryoprotectants created from combinations of natural and synthetic compounds. One project from the National Institutes of Health in the U.S. simulated over 10,000 cryoprotectant mixtures in just 72 hours, which would have taken over a decade using traditional computing. Several promising candidates from this research are now entering animal trials.